Spinal Anaesthesia
Spinal anaesthesia involves injection of local anaesthetic into the subarachnoid space producing rapid, dense sensory and motor block with predictable dermatomal distribution. Mechanism: Local anaesthetic acts on...
Clinical board
A visual summary of the highest-yield teaching signals on this page.
Urgent signals
Safety-critical features pulled from the topic metadata.
- Total spinal with cardiovascular collapse and respiratory failure
- High spinal causing severe hypotension and bradycardia
- Post-dural puncture headache (PDPH) preventing ambulation
- Cauda equina syndrome from neurotoxicity
Exam focus
Current exam surfaces linked to this topic.
- ANZCA Final Written
- ANZCA Final Clinical Viva
- ANZCA Final Medical Viva
Editorial and exam context
Quick Answer
Spinal anaesthesia involves injection of local anaesthetic into the subarachnoid space producing rapid, dense sensory and motor block with predictable dermatomal distribution. Mechanism: Local anaesthetic acts on nerve roots and spinal cord blocking sodium channels, with small unmyelinated C fibers (pain) blocked before large myelinated A fibers (motor). Technique: Midline or paramedian approach at L3-L4 or L4-L5 interspace (below conus medullaris which ends at L1-L2 in adults), using 25-27G pencil-point needles (Whitacre, Sprotte) to reduce PDPH risk. Standard caesarean section dose: Hyperbaric bupivacaine 0.5% 2.2-2.5 mL (11-12.5 mg) with fentanyl 10-20 μg and morphine 100-200 μg for postoperative analgesia. Onset: 2-5 minutes (faster than epidural), duration 90-180 minutes depending on drug/dose. Hypotension occurs in 15-30% due to sympathetic blockade (T4-L1), managed with left uterine displacement, fluid preload 500-1000 mL, phenylephrine 50-100 μg IV bolus or infusion 50-100 μg/min. PDPH incidence 1-2% with modern needles, treated with epidural blood patch (15-20 mL autologous blood) if severe/persistent. Contraindications: Patient refusal, coagulopathy (platelets <80 × 10⁹/L), infection at site, severe hypovolaemia, increased ICP. Indigenous patients have higher rates of obesity and OSA increasing technical difficulty and PDPH risk, requiring careful positioning and culturally sensitive consent processes. [1-10]